Nano Formulation Devices Technology for Targeting Breast Cancer Chemotherapy
Niladri Shekhar Dey*, Sibaji Sarkar, Tanmay Mohanta and Subhasish Pramanik
ABSTRACT
Cancer, a multifaceted illness, entails unchecked and atypical cell growth, resulting in tumours, invasion, and spreading. The majority of antineoplastic medications are neither specific nor selective for malignant cells. Therefore, they exert a significant toxic impact on normal healthy cells. This typically relates to the dosage and administration schedule (frequency of administration) for any cancer treatments. Breast carcinoma poses a significant health issue for women globally. Therefore, the primary emphasis of cancer treatment must prioritize greater selectivity of chemotherapeutic agents towards the neoplastic cells while preventing their effect on the normal healthy cells. Nanocarriers for drugs are now being utilized to enhance traditional cancer chemotherapy. Numerous nanoscale active ingredient molecule carriers are designed to deliver the medication to the specific location to prevent dose related toxicity, while improving drug effectiveness, biocompatibility, and stability. Nanoformulations enhance the duration that active pharmaceutical ingredients stay in the bloodstream, resulting in the build-up of medicine within cancer cells because of their “permeable blood vessels.” Nanoformulations can effectively reach cells or tissues through mechanisms of “active or passive targeting”. The passive targeting mechanism affects the tumour environment, enabling the vesicular flexibility of nanodevices to penetrate neoplastic cells and accumulate within them due to the “enhanced permeability and retention effect.” The nanoparticle formulations for cancer treatment could be enhanced by incorporating targeted ligands linked to the molecules on the nanodevice surfaces, enabling precise drug delivery to cancerous cells.
